Sudarshan Pharma Industries MD, chairman, board of directors and AGM
BSE: 543828Chemicals & PetrochemicalsSmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹32.57.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹795 Cr1,697th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 31.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 4 Jun 2026
- 1.81
- Volume, BSEVolume. Shares traded on the last trading day.
- 40,000
Sudarshan Pharma Industries board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.
- Chairperson and managing directorHemal Vasantrai Mehta
- Managing directorSachin Vasantrai Mehta
- Company Secretary and Compliance OfficerNirav Shah
8 directors4 independent2 executive2 non-executive
- Hemal Vasantrai Mehta · Chairperson and managing directorExecutive · joined Jan 2015 · reappointed Oct 2023 · 60 months as independent · 1 listed board · 2 committee seats
- Sachin Vasantrai Mehta · Managing directorExecutive · joined Jul 2008 · reappointed Oct 2023 · 60 months as independent · 1 listed board · 1 committee seat
- Jaya Ankur SinghaniaIndependent · joined Dec 2022 · reappointed Dec 2022 · 60 months as independent · 4 listed boards · 4 as independent · 7 committee seats, 3 as chair
- Rushabh Prashant PatilIndependent · joined Jul 2023 · reappointed Sep 2023 · 60 months as independent · 2 listed boards · 2 as independent · 3 committee seats, 1 as chair
- Anil Balkrishna GhogareNon-executive · joined Nov 2023 · reappointed Feb 2024 · 12 months as independent · 1 listed board
- Vijay OjhaIndependent · joined Oct 2025 · reappointed Jan 2026 · 60 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
- Vinay Kumar PandeyNon-executive · joined May 2026 · reappointed Jun 2026 · 12 months as independent · 1 listed board
- Sanat BhatIndependent · joined May 2026 · reappointed Jun 2026 · 60 months as independent · 1 listed board · 1 as independent
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- Umesh Luthra, left 18 Oct 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 5 Sep 20265 of 8 present2 independent · 23 days in between
- 12 Aug 20264 of 8 present3 independent · 82 days in between
- 21 May 20268 of 8 present4 independent
Audit Committee
Chair Rushabh Prashant Patil
Vijay Ojha, Hemal Vasantrai Mehta
- 12 Aug 20262 of 3 present2 independent · 103 days in between
- 30 Apr 20263 of 3 present2 independent
Nomination and remuneration committee
Chair Rushabh Prashant Patil
Jaya Ankur Singhania, Vijay Ojha
No meeting listed in the filing.
Stakeholders Relationship Committee
Chair Vijay Ojha
Hemal Vasantrai Mehta, Sachin Vasantrai Mehta
No meeting listed in the filing.
Corporate Social Responsibility Committee
Chair Hemal Vasantrai Mehta
Sachin Vasantrai Mehta, Rushabh Prashant Patil
No meeting listed in the filing.
Warrants Committee
Chair Jaya Ankur Singhania
Hemal Vasantrai Mehta, Sachin Vasantrai Mehta
No meeting listed in the filing.
FCCB Committee
Chair Jaya Ankur Singhania
Vinay Kumar Pandey, Sachin Vasantrai Mehta
- 19 Aug 20263 of 3 present1 independent · 6 days in between
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- NGST & AssociatesPeer-review certificate valid to Aug 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Sudarshan Pharma Industries AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Sudarshan Pharma Industries dividend history
Annual general meeting, 22 Sep 2026
1,250 shareholders on the register on 15 Sep 2026; present: 6 promoters and 9 others; votes counted by Vishal N Manseta / Vishal N Manseta.The company's voting result (opens in a new tab)
To adopt the audited standalone financial statements (including consolidated financial statements) of the Company for the financial year ended 31st March, 2026 together with the Reports of the Board of Directors and the Auditors thereonMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 31.10% · promoters 51.19% · institutions 0.00% · other public 4.51%
- To appoint a director in place of Dr. Anil Ghogare (DIN - 00432659), who retires by rotation and being eligible, offers himself for re-appointmentOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 31.10% · promoters 51.19% · institutions 0.00% · other public 4.51%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Tax disputes
Reported in the filing for the quarter to Sep 2026.
- Tax disputeIncome Tax AuthoritiesSince 28 Oct 2021OngoingAt the filing before: Demand under Section 270A of the Income Tax Act, 1961 pertaining to Assessment Year 2017-18
- Tax disputeIncome Tax AuthoritiesSince 7 May 2025OngoingAt the filing before: Demand under Section 154 of the Income Tax Act, 1961 pertaining to Assessment Year 2023-24
- Tax disputeIncome Tax AuthoritiesSince 28 Mar 2025OngoingAt the filing before: Demand under Section 144 of the Income Tax Act, 1961 pertaining to Assessment Year 2022-23
- Tax disputeTDS AuthoritiesSince 31 May 2010OngoingAt the filing before: TRACES demand for the Financial Year 2009-10
- Tax disputeTDS AuthoritiesSince 31 May 2011OngoingAt the filing before: TRACES demand for the Financial Year 2010-11
- Tax disputeTDS AuthoritiesSince 31 May 2024OngoingAt the filing before: TRACES demand for the Financial Year 2023-24
- Tax disputeTDS AuthoritiesSince 31 May 2025OngoingAt the filing before: TRACES demand for the Financial Year 2024-25
- Tax disputeTDS AuthoritiesSince 27 Mar 2026OngoingAt the filing before: TRACES demand for the Financial Year 2025-26
15 more
- Tax disputeTDS AuthoritiesSince 3 Aug 2026OngoingAt the filing before: TRACES demand for the Financial Year 2026-27
- Tax disputeGST AuthoritiesSince 26 Dec 2023OngoingAt the filing before: Claim under Section 73 of the GST Act for FY 2017-18
- Tax disputeGST AuthoritiesSince 23 Aug 2024OngoingAt the filing before: Investigation Sales Tax (MB Machinery) for FY 2019-20
- Tax disputeGST AuthoritiesSince 23 Aug 2024OngoingAt the filing before: Investigation Sales Tax (MB Machinery) for FY 2020-21
- Tax disputeGST AuthoritiesSince 23 Aug 2024OngoingAt the filing before: Investigation Sales Tax (MB Machinery) for FY 2021-22
- Tax disputeGST AuthoritiesSince 23 Aug 2024OngoingAt the filing before: Investigation Sales Tax (MB Machinery) for FY 2022-23
- Tax disputeGST AuthoritiesSince 27 Jan 2025OngoingAt the filing before: Investigation Sales Tax for FY 2017-18
- Tax disputeGST AuthoritiesSince 27 Jan 2025OngoingAt the filing before: Claim under Section 73 of the GST Act for FY 2017-18
- Tax disputeGST AuthoritiesSince 4 Dec 2025OngoingAt the filing before: Claim under Section 73 of the GST Act for ALORA TRADING COMPANY LIMITED
- Tax disputeGST AuthoritiesSince 12 Dec 2025OngoingAt the filing before: Claim under Section 73 of the GST Act for RAJ SOLVENT PRIVATE LIMITED
- Tax disputeGST AuthoritiesSince 18 Dec 2025OngoingAt the filing before: Claim under Section 73 of the GST Act for VSV PRODUCTS
- Tax disputeGST AuthoritiesSince 24 Dec 2025OngoingAt the filing before: Claim under Section 73 of the GST Act for LEMON HEALTHCARE
- Tax disputeGST AuthoritiesSince 31 Dec 2025OngoingAt the filing before: Claim under Section 73 of the GST Act for SURVIVAL TECHNOLOGIES PRIVATE LIMITED
- Tax disputeGST AuthoritiesSince 30 Dec 2025OngoingAt the filing before: Claim under Section 73 of the GST Act
- Tax disputeGST AuthoritiesSince 27 Mar 2026OngoingAt the filing before: Claim under Section 74 of the GST Act VAMA TRADERS
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- Yes
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far. A statement's amounts are left out where the raise it states is more than ten times everything the company owns, a figure typed at the wrong scale.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| OthersJun 2026 | – | – | – | No | |
| Preferential IssuesJun 2026 | – | – | – | No |